Kombiglyze XR pills approved in Korea for treatment of type 2 diabetes in adults
Published: 2012-05-30 06:56:00
Updated: 2012-05-30 06:56:00
Bristol-Myers Squibb (BMS) Korea announced Sunday that the Korea Food and Drug Administration approved Kombiglyze XR tablets 2.5/1000mg for the treatment of type 2 diabetes in adults, following its approval of the same brand 5/500mg and 5/1000mg on April 12.
Co-developed by AstraZeneca, Kombig...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
